Torthaí cuardaigh - Scott, Charlie

  • 1 - 5 toradh as 5 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial

    Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial de réir Rossing, Peter, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Amod, Aslam, Marre, Michel, Joseph, Amer, Lage, Andrea, Scott, Charlie, Bakris, George L.

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán
    Téacs
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial

    Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial de réir Agarwal, Rajiv, Joseph, Amer, Anker, Stefan D., Filippatos, Gerasimos, Rossing, Peter, Ruilope, Luis M., Pitt, Bertram, Kolkhof, Peter, Scott, Charlie, Lawatscheck, Robert, Wilson, Daniel J., Bakris, George L.

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán
    Téacs
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study

    Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study de réir Rossing, Peter, Burgess, Ellen, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Gillard, Pieter, MacIsaac, Richard J., Wainstein, Julio, Joseph, Amer, Brinker, Meike, Roessig, Lothar, Scott, Charlie, Bakris, George L.

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán
    Téacs
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

    Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy de réir Rossing, Peter, Filippatos, Gerasimos, Agarwal, Rajiv, Anker, Stefan D., Pitt, Bertram, Ruilope, Luis M., Chan, Juliana C.N., Kooy, Adriaan, McCafferty, Kieran, Schernthaner, Guntram, Wanner, Christoph, Joseph, Amer, Scheerer, Markus F., Scott, Charlie, Bakris, George L.

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán
    Téacs
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results

    Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results de réir Agarwal, Rajiv, Anker, Stefan D, Filippatos, Gerasimos, Pitt, Bertram, Rossing, Peter, Ruilope, Luis M, Boletis, John, Toto, Robert, Umpierrez, Guillermo E, Wanner, Christoph, Wada, Takashi, Scott, Charlie, Joseph, Amer, Ogbaa, Ike, Roberts, Luke, Scheerer, Markus F, Bakris, George L

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán
    Téacs
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: